Pedro Jares

19.1k total citations · 1 hit paper
101 papers, 4.7k citations indexed

About

Pedro Jares is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Pedro Jares has authored 101 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 43 papers in Molecular Biology and 40 papers in Pathology and Forensic Medicine. Recurrent topics in Pedro Jares's work include Lymphoma Diagnosis and Treatment (30 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Cancer-related Molecular Pathways (17 papers). Pedro Jares is often cited by papers focused on Lymphoma Diagnosis and Treatment (30 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Cancer-related Molecular Pathways (17 papers). Pedro Jares collaborates with scholars based in Spain, United States and Germany. Pedro Jares's co-authors include Elı́as Campo, Dolors Colomer, Sı́lvia Beà, Pedro L. Fernández, J. Julian Blow, Antonio Cardesa, Magda Pinyol, Francesc Bosch, Neus Villamor and Iracema Nayach and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Pedro Jares

98 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Non-coding recurrent mutations in chronic lymphocytic leukaemia

2016 377 citations Xosé S. Puente, Sı́lvia Beà et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pedro Jares Spain	35	2.2k	2.1k	2.0k	1.3k	697	101	4.7k
Manuela Mollejo Spain	45	3.1k 1.4×	1.7k 0.8×	1.2k 0.6×	2.2k 1.7×	633 0.9×	133	5.3k
Sı́lvia Beà Spain	40	2.8k 1.3×	1.9k 0.9×	1.9k 1.0×	1.6k 1.3×	694 1.0×	97	4.8k
Lisa M. Rimsza United States	42	3.5k 1.6×	2.6k 1.3×	1.4k 0.7×	1.6k 1.2×	398 0.6×	199	6.2k
José A. Martínez-Climent Spain	39	1.0k 0.5×	1.3k 0.6×	1.9k 1.0×	865 0.7×	784 1.1×	135	4.5k
Christian Bastard France	46	3.1k 1.4×	2.3k 1.1×	2.5k 1.2×	2.0k 1.6×	527 0.8×	152	6.4k
Cristina Mecucci Italy	47	1.4k 0.6×	1.5k 0.7×	4.1k 2.1×	2.5k 2.0×	905 1.3×	265	9.5k
Valter Gattei Italy	43	2.4k 1.1×	1.4k 0.7×	1.7k 0.8×	2.5k 2.0×	499 0.7×	222	5.7k
Andreas Bräuninger Germany	34	2.4k 1.1×	1.8k 0.9×	1.1k 0.5×	936 0.7×	487 0.7×	77	3.9k
Christian Steidl Canada	44	3.3k 1.5×	2.5k 1.2×	2.2k 1.1×	1.5k 1.2×	764 1.1×	184	6.5k
Yasuhiro Oki United States	40	3.1k 1.4×	2.3k 1.1×	2.2k 1.1×	1.7k 1.3×	312 0.4×	207	6.3k

Countries citing papers authored by Pedro Jares

Since Specialization

Citations

This map shows the geographic impact of Pedro Jares's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro Jares with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro Jares more than expected).

Fields of papers citing papers by Pedro Jares

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pedro Jares. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro Jares. The network helps show where Pedro Jares may publish in the future.

Co-authorship network of co-authors of Pedro Jares

This figure shows the co-authorship network connecting the top 25 collaborators of Pedro Jares. A scholar is included among the top collaborators of Pedro Jares based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pedro Jares. Pedro Jares is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pineda, Estela, Ainhoa Hernández, Marta Doménech, et al.. (2024). The C250T Mutation of TERTp Might Grant a Better Prognosis to Glioblastoma by Exerting Less Biological Effect on Telomeres and Chromosomes Than the C228T Mutation. Cancers. 16(4). 735–735. 1 indexed citations

Schettini, Francesco, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2023). 55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC). ESMO Open. 8(1). 101279–101279. 1 indexed citations

Martínez‐Sáez, Olga, Fara Brasó‐Maristany, Mercedes Marín‐Aguilera, et al.. (2023). 8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer. ESMO Open. 8(1). 101232–101232.

Rodríguez, A., Laia Fernández‐Barat, F. Espósito, et al.. (2022). Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53–Mutated Metastatic Colorectal Cancer. Cancers. 14(23). 5921–5921. 3 indexed citations

Balsas, Patricia, Ferran Nadeu, Álvaro Eguileor, et al.. (2022). Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma. Leukemia. 37(2). 408–421. 4 indexed citations

Calbet‐Llopart, Neus, et al.. (2021). Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions. Diagnostics. 11(8). 1319–1319. 5 indexed citations

Victoria, Iván, Pedro Jares, Núria Viñolas, et al.. (2021). Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice. Journal of Thoracic Disease. 13(3). 1658–1670. 5 indexed citations

Demajo, Santiago, Guillem Clot, Giancarlo Castellano, et al.. (2020). A Cyclin D1–Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. Clinical Cancer Research. 27(1). 213–225. 10 indexed citations

Reyes, Roxana, Clara Mayo‐de‐las‐Casas, Cristina Teixidó, et al.. (2019). Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report. Clinical Lung Cancer. 20(3). e219–e223. 15 indexed citations

10.

Teixidó, Cristina, Ramón M. Marrades, Núria Viñolas, et al.. (2019). EP1.01-41 Feasibility of EBUS-TBNA Cytologies for an Extensive Assessment of Predictive Biomarkers in Lung Cancer. Journal of Thoracic Oncology. 14(10). S927–S928. 1 indexed citations

11.

Pedrosa, Leire, Juan Moreno, F. Espósito, et al.. (2019). Immune signatures identify three immune clusters in mCRC, with potential clinical implications. Annals of Oncology. 30. iv120–iv120. 1 indexed citations

12.

Puente, Xosé S., Pedro Jares, & Elı́as Campo. (2018). Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood. 131(21). 2283–2296. 78 indexed citations

13.

Navarro, Alba, Sı́lvia Beà, Verónica Fernández, et al.. (2009). MicroRNA Expression, Chromosomal Alterations, and Immunoglobulin Variable Heavy Chain Hypermutations in Mantle Cell Lymphomas. Cancer Research. 69(17). 7071–7078. 60 indexed citations

14.

Enjuanes, Anna, Yolanda Benavente, Francesc Bosch, et al.. (2008). Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia. Cancer Research. 68(24). 10178–10186. 60 indexed citations

15.

Schraders, Margit, Pedro Jares, Sı́lvia Beà, et al.. (2008). Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene‐dosage regulated candidate genes. British Journal of Haematology. 143(2). 210–221. 21 indexed citations

16.

Camós, Mireia, Jordi Esteve, Pedro Jares, et al.. (2006). Gene Expression Profiling of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13) and MYST3-CREBBP Rearrangement Reveals a Distinctive Signature with a Specific Pattern of HOX Gene Expression. Cancer Research. 66(14). 6947–6954. 91 indexed citations

17.

Jares, Pedro & Elı́as Campo. (2006). Genomic platforms for cancer research: potential diagnostic and prognostic applications in clinical oncology. Clinical & Translational Oncology. 8(3). 161–172. 6 indexed citations

18.

Ramis, Isabel, G. Bioque, José A. Lorente, et al.. (2000). Constitutive nuclear factor-kappaB activity in human upper airway tissues and nasal epithelial cells. European Respiratory Journal. 15(3). 582–589. 19 indexed citations

19.

Jares, Pedro, Pedro L. Fernández, Alfons Nadal, et al.. (1997). p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. Oncogene. 15(12). 1445–1453. 40 indexed citations

20.

Clausse, Nathalie, Pascale Jackers, Pedro Jares, et al.. (1996). Identification of the Active Gene Coding for the Metastasis-Associated 37LRP/p40 Multifunctional Protein. DNA and Cell Biology. 15(12). 1009–1023. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact